Sponsor:
Pediatric Brain Tumor Consortium
Code:
NCT04978727
Conditions
Medulloblastoma
Glioblastoma Multiforme
Anaplastic Astrocytoma
High-grade Astrocytoma NOS
Anaplastic Oligodendroglioma
Eligibility Criteria
Sex: All
Age: 1 - 21
Healthy Volunteers: Not accepted
Interventions
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥1 and <10 years
SurVaxM for patients with non-relapsed DIPG post radiation-therapy ages ≥1 and ≤21 years
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-29. This information was provided to ClinicalTrials.gov by Pediatric Brain Tumor Consortium on 2025-03-25.